AstraZeneca PLC's revived lupus asset, anifrolumab, is on the way to joining GlaxoSmithKline PLC's Benlysta on the market after the full data set from a second Phase III trial showed that the type I interferon blocker could be an effective treatment for the under-served complex autoimmune disease.
AstraZeneca Closer To Filing Anifrolumab For Lupus
Success After Switching Endpoints In TULIP 2
Having recovered from a late-stage fail last year, AstraZeneca has fleshed out results from a positive second Phase III trial of anifrolumab which it hopes will be the second new lupus treatment to hit the market in 60 years.
